Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: A retrospective, matched-cohort study

The Lancet Haematology

Volumn 2, Issue 4, 2015, Pages e150-e159

  Bouillon, Kim ^a   Bertrand, Marion ^a   Maura, Géric ^b   Blotière, Pierre Olivier ^b   Ricordeau, Philippe ^b   Zureik, Mahmoud ^a  

^a French National Agency for Medicines and Health Products Safety   (France)

^b National Health Insurance   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; FLUINDIONE; RIVAROXABAN; WARFARIN; PHENINDIONE; VITAMIN K GROUP;

ADULT; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW (TOPIC); AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPLICATION; RISK FACTOR; STROKE; THROMBOEMBOLISM; VERY ELDERLY;

ACENOCOUMAROL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; MALE; PHENINDIONE; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; STROKE; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84944715132     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00027-7     Document Type: Article

References (33)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
3. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009; 374: 1196-208.
4. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-47.
5. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ. Trends in anticoagulation for atrial fibrillation in the US: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol 2007; 49: 1561-65.
6. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart Br Card Soc 2006; 92: 1064-70.
7. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation. Circulation 2010; 122: 2246-53.
8. Mahaffey KW, Wojdyla D, Hankey GJ, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013; 158: 861-68.
9. Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013; 3: e002758.
10. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GYH. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-56.
11. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014; 127: 329-36.
12. Fagot J-P, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011; 29: 3610-16.
13. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-62.
14. Neumann A, Maura G, Weill A, Ricordeau P, Alla F, Allemand H. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf 2014; 23: 240-50.
15. Tuppin P, Ricci-Renaud P, de Peretti C, et al. Frequency of cardiovascular diseases and risk factors treated in France according to social deprivation and residence in an overseas territory. Int J Cardiol 2014; 173: 430-35.
16. Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010; 19: 1256-62.
17. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidémiol Sante Publique 2010; 58: 286-90.
18. Durrieu G, Batz A, Rousseau V, Bondon-Guitton E, Petiot D, Montastruc JL. Use of administrative hospital database to identify adverse drug reactions in a Pediatric University Hospital. Eur J Clin Pharmacol 2014; 70: 1519-26.
19. Le Heuzey J-Y, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833-41.
20. Witt DM, Delate T, Clark NP, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114: 952-56.
21. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates, 1988.
22. Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS, 2012. http://support.sas.com/resources/papers/proceedings12/335-2012.pdf (accessed Feb 18, 2015).
23. Cox D. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
24. Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997.-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 2009; 9: 33.
25. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
26. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
27. Greenland S. Invited commentary: variable selection versus shrinkage in the control of multiple confounders. Am J Epidemiol 2008; 167: 523-29; discussion 530-31.
28. French Institute for Public Health Surveillance Databases of chronic diseases and injuries. Calibration of PMSI MCO database in the surveillance of myocardial infarction in 2003. 2010. http://opac.invs.sante.fr/doc_num.php?explnum_id=250 (accessed Feb 18, 2015).
29. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-57.
30. Schoof N, Schnee J, Schneider G, et al. Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin 2014; 30: 795-804.
31. Garg AX, Meirambayeva A, Huang A, et al. Cardiovascular disease in kidney donors: matched cohort study. BMJ 2012; 344: e1203.
32. Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 2012; 345: e4447.
33. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. London: Lippincott Williams and Wilkins, 2008.